Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocular Therapeutix

12.03
+0.27502.34%
Volume:705.95K
Turnover:8.50M
Market Cap:1.92B
PE:-10.46
High:12.21
Open:11.92
Low:11.84
Close:11.75
Loading ...

After Leaping 31% Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Are Not Flying Under The Radar

Simply Wall St.
·
Yesterday

Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025

GlobeNewswire
·
29 Jul

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

GlobeNewswire
·
22 Jul

Institutional investors control 65% of Ocular Therapeutix, Inc. (NASDAQ:OCUL) and were rewarded last week after stock increased 3.7%

Simply Wall St.
·
07 Jul

Ocular Therapeutix Inc. Files Initial Statement of Beneficial Ownership for Chief Business Officer Namrata Saroj

Reuters
·
24 Jun

Ocular Therapeutix Amends Bylaws to Expand Stock Plans and Update Director Exculpation

Reuters
·
12 Jun

Chief Medical Officer Nadia Waheed Reports Disposal of Common Shares of Ocular Therapeutix Inc

Reuters
·
04 Jun

Ocular Therapeutix Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
30 May

Clear Street Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)

TIPRANKS
·
29 May

Ocular Shares Rise After Eye Disease Trial Nears Enrollment Completion

MT Newswires Live
·
29 May

Strong Buy Rating for Ocular Therapeutix Driven by Promising Axpaxli Program and Market Potential

TIPRANKS
·
28 May

Ocular Therapeutix to close enrollment this week for SOL-R

TIPRANKS
·
28 May

Ocular Therapeutix Chief Strategy Officer Sanjay Nayak Reports Disposal of Common Shares

Reuters
·
28 May

Pravin Dugel, Director and Officer of Ocular Therapeutix Inc., Reports Disposal of Common Shares

Reuters
·
28 May

Director Richard L. Lindstrom, MD Reports Acquisition of Common Shares in Ocular Therapeutix Inc

Reuters
·
13 May

Ocular Therapeutix (OCUL) Gets a Buy from Scotiabank

TIPRANKS
·
06 May

Ocular Therapeutix Is Maintained at Buy by Needham

Dow Jones
·
06 May

Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings

Benzinga
·
06 May

Strategic Advancements and Financial Updates Drive Buy Rating for Ocular Therapeutix

TIPRANKS
·
06 May

Ocular Therapeutix Stock Falls as 1Q Misses Targets, R&D Expenses Double

Dow Jones
·
05 May